Table 1 Discovery cohort: clinicopathological data of the Tumor Profiler Melanoma cohort used as the discovery cohort.
From: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
Clinicopathological parameters patients (n = 116) | Site of metastasis (n = 126) | |||||||
|---|---|---|---|---|---|---|---|---|
Brain (n = 15) | Soft tissue (n = 59) | LN (n = 37) | Other (n = 15) | |||||
No. | % | No. | % | No. | % | No. | % | |
Gender | ||||||||
F | 7 | 46.7 | 28 | 47.5 | 12 | 32.4 | 5 | 33.3 |
M | 8 | 53.3 | 31 | 52.5 | 25 | 67.6 | 10 | 66.7 |
Age (years) | ||||||||
<40 | 2 | 13.3 | 3 | 5.1 | 2 | 5.4 | 2 | 13.3 |
40–49 | 3 | 20.0 | 2 | 3.4 | 2 | 5.4 | 5 | 33.3 |
50–59 | 6 | 40.0 | 16 | 27.1 | 13 | 35.1 | 1 | 6.7 |
60–69 | 1 | 6.7 | 16 | 27.1 | 8 | 21.6 | 2 | 13.3 |
70–79 | 2 | 13.3 | 19 | 32.2 | 8 | 21.6 | 5 | 33.3 |
≥80 | 1 | 6.7 | 3 | 5.1 | 4 | 10.8 | 0 | 0 |
Histological subtype | ||||||||
Cutaneous | 12 | 80.0 | 43 | 72.9 | 31 | 83.8 | 10 | 66.7 |
Mucosal | 0 | 0.0 | 3 | 5.1 | 1 | 2.7 | 3 | 20.0 |
Ocular | 1 | 6.7 | 8 | 13.6 | 0 | 0.0 | 2 | 13.3 |
Unknown primary | 2 | 13.3 | 5 | 8.5 | 5 | 13.5 | 0 | 0.0 |
Stage | ||||||||
III | 0 | 0.0 | 13 | 22.0 | 19 | 51.4 | 1 | 6.7 |
IV | 15 | 100.0 | 46 | 78.0 | 18 | 48.6 | 14 | 93.3 |
Immune diagnosis | ||||||||
Desert | 7 | 46.7 | 19 | 32.2 | 8 | 21.6 | 2 | 13.3 |
Excluded | 5 | 33.3 | 26 | 44.1 | 21 | 56.8 | 10 | 66.7 |
Inflamed | 2 | 13.3 | 10 | 16.9 | 6 | 16.2 | 3 | 20.0 |
Dual phenotype | 1 | 6.7 | 4 | 6.8 | 2 | 5.4 | 0 | 0.0 |
